Archive ready
新型コロナウイルス治療薬の特例承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_23047.htmlApril 10, 2026 at 03:02 AM JST•The archive page, viewer, and downloads use this saved version.
April 10, 2026 at 03:02 AM JST·www.mhlw.go.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved page
新型コロナウイルス治療薬の特例承認について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
Original URLhttps://www.mhlw.go.jp/stf/newpage_23047.html
StartedApril 10, 2026 at 03:02 AM JST
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
About this pageAI generated
This page announces the exceptional approval of a COVID-19 treatment drug by Japan's Ministry of Health, Labour and Welfare on December 24, 2021. Under Article 14-3 of the Pharmaceutical Affairs Law, "Lagevrio Capsule 200mg" (generic name: molnupiravir), submitted by MSD Co., Ltd., received special approval for treating SARS-CoV-2 infections. The application was filed on December 3, 2021, with accompanying prescribing information provided separately.
